Related Experiment Videos

Clarithromycin use and risk of death in patients with ischemic heart disease

Søren Skøtt Andersen1, Morten Lock Hansen, Mette Lykke Norgaard

  • 1Department of Cardiology, Gentofte Hospital, Copenhagen, Denmark. ssa@heart.dk

Cardiology
|June 5, 2010
PubMed

Insights

Clarithromycin use in patients with ischemic heart disease (IHD) for H. pylori eradication did not increase mortality risk. This antibiotic treatment is safe for IHD patients, showing no significant difference in death rates over five years.

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Ischemic heart disease (IHD) is a significant global health concern.
  • Antibiotic use, particularly clarithromycin, is common for Helicobacter pylori eradication.
  • Concerns exist regarding the cardiovascular safety of clarithromycin.

Purpose of the Study:

  • To investigate the association between clarithromycin treatment and all-cause mortality in patients with pre-existing ischemic heart disease (IHD).

Main Methods:

  • Nationwide registers were used to identify IHD patients from 1997-2007 who received dual antibiotic treatment.
  • The primary endpoint assessed was all-cause mortality.
  • A comparison was made between IHD patients undergoing eradication therapy and those who were not.

Main Results:

  • The study included 214,330 individuals with IHD.
  • No increased risk of all-cause mortality was observed in patients treated with clarithromycin compared to those not receiving eradication therapy (HR 1.02; 95% CI 0.84-1.23).
  • The findings remained consistent over a 5-year follow-up period.

Conclusions:

  • Clarithromycin use for Helicobacter pylori eradication in patients with ischemic heart disease is not associated with an increased risk of death.
  • The findings support the safety of clarithromycin in this patient population.
  • Further research may explore long-term cardiovascular outcomes.
Abstract

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...